These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 36932227)

  • 1. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.
    Llovet JM; Willoughby CE; Singal AG; Greten TF; Heikenwälder M; El-Serag HB; Finn RS; Friedman SL
    Nat Rev Gastroenterol Hepatol; 2023 Aug; 20(8):487-503. PubMed ID: 36932227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
    Chen Y; Wang W; Morgan MP; Robson T; Annett S
    Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    Foerster F; Gairing SJ; Müller L; Galle PR
    J Hepatol; 2022 Feb; 76(2):446-457. PubMed ID: 34555422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
    Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
    World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From NASH to HCC: current concepts and future challenges.
    Anstee QM; Reeves HL; Kotsiliti E; Govaere O; Heikenwalder M
    Nat Rev Gastroenterol Hepatol; 2019 Jul; 16(7):411-428. PubMed ID: 31028350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of CD4
    Miao Y; Li Z; Feng J; Lei X; Shan J; Qian C; Li J
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.
    Weinmann A; Alt Y; Koch S; Nelles C; Düber C; Lang H; Otto G; Zimmermann T; Marquardt JU; Galle PR; Wörns MA; Schattenberg JM
    BMC Cancer; 2015 Apr; 15():210. PubMed ID: 25884354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
    Marengo A; Rosso C; Bugianesi E
    Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
    J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of CD8
    Zhong X; Lv M; Ma M; Huang Q; Hu R; Li J; Yi J; Sun J; Zhou X
    Biomed Pharmacother; 2023 Sep; 165():115131. PubMed ID: 37429231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
    Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.